Home -> Law Blog Directory -> Personal Injury Law Blogs -> Atlanta Personal Injury Lawyer
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Personal Injury Law
: Atlanta Personal Injury LawyerNew Labeling Added By FDA from Infections Linked to Transplant Drugs
By Jessica Smagacz
According to MSNBC, this past Tuesday, Federal health regulators said they were going to add new labels regarding the risks of infection to organ transplant drugs made by several drugmakers. Some of those drugmakers include Roche and Novartis.
This move is a result of FDA receiving reports of dangerous viral infections in patients who took these drugs, 'which are typically used to avoid rejection following kidney transplant.'
The drugs that will have these new labels include: Roche's CellCept, Novartis' Myfortic, Wyeth's Rapamune, Neoral, and Sandimmune.
FDA is continuing to monitor any reports of safety problems with these medications. FDA has also said that 'physicians should carefully monitor patients for signs of viral infection, which can sometimes lead to kidney failure.'
Originally posted at InjuryBoard by Jessica Smagacz
Full post as published by Atlanta Personal Injury Lawyer on July 19, 2009 (boomark / email).
Wyeth Sued Over Rapamune Transplant Drug
Illegal Marketing of Rapamune Sparks Lawsuit
Wrinkle-Fillers
FDA to Review Labeling due to Adverse Event Reports
Transdermal Drug Patches
Risk of Burns Missing From Some Labeling
Dobutamine Hydrochloride Injection
Labeling Errors Prompts Recall of 250 mg/20 ml Injections
GlaxoSmithKline Pays $750 Million Over Defective Drugs
GlaxoSmithKline Pays $750 Million Over Defective Drugs
San Antonio Bay Oysters Linked to Virus
Oysters Linked to Contagious Virus

FDA Orders Labeling Changes for Anemia Drugs
Paxil and Other Drugs to Get Labeling Change
Several Drugs Found to be Linked to Suicide
First American facial transplant recipient recovering
October 2007 FDA Posting - Changes you should read.








